ArticleMycoses2026
High-Volume Culture Improves Diagnostic Yield of Aspergillus Species From Sputum.
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSputum is a commonly collected specimen for suspected respiratory fungal infections due to its non-invasive nature and diagnostic value. However, conventional culture at 29°C (CC29) often fails to detect filamentous moulds. To improve recovery, we applied a high-volume culture incubated at 37°C (HVC37) and compared its diagnostic performance with CC29, with particular focus on Aspergillus species and azole-resistant isolates.
methodsBetween October 2022 and June 2025, a total of 1546 sputum samples from 793 patients, including 219 samples from 67 patients with chronic pulmonary aspergillosis (CPA), were cultured in parallel using HVC37 (0.5-1 mL inoculum) and CC29 (1-10 μL inoculum) on Sabouraud agar for 7 days. Positivity rates for moulds and Aspergillus species were calculated with 95% confidence intervals. Antifungal susceptibility testing followed EUCAST standards.
resultsHigh-volume culture incubated at 37°C (HVC37) markedly outperformed CC29 for detection of both moulds and Aspergillus species. Across all sputum samples, HVC37 achieved a mould positivity rate of 41.6% (95% CI 39.2%-44.1%) versus 27.7% (95% CI 25.5%-30.0%) with CC29. The improvement was most evident for Aspergillus detection: 37.0% (95% CI 34.7%-39.5%) for HVC37 compared with 11.5% (95% CI 10.0%-13.2%) for CC29, an absolute increase of 25.5%. Both methods together yielded the highest overall detection rates for moulds (54.0%) and Aspergillus species (42.1%). In patients with CPA, HVC37 detected moulds in 53.0% of samples and Aspergillus species in 45.2%, compared with 30.6% and 15.5%, respectively, for CC29. Importantly, of 46 azole-resistant A. fumigatus isolates recovered, HVC37 detected 42 (91.3%), whereas CC29 detected only 20 (43.5%). CC29 mainly identified environmental moulds such as Penicillium species, not detected by HVC37.
conclusionsHigh-volume culture at 37°C substantially improves the detection of filamentous moulds in sputum, especially Aspergillus species and clinically relevant azole-resistant A. fumigatus. Incorporating HVC37 into routine mycology workflows can significantly enhance fungal diagnosis and antifungal resistance surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.